Inventor

Gerhard Siemeister

Inventor

Berlin, DE

Overview

2004–2020

Patent span

Human necessities

Primary field (CPC A)

Patents· 73 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations33%

C07DHeterocyclic compounds32%

A61KPreparations for medical, dental or toiletry purposes24%

C07CAcyclic or carbocyclic compounds4%

C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium3%

A01HNew plants or non-transgenic processes for obtaining them1%

C07BGeneral methods of organic chemistry1%

Y02ATechnologies for adaptation to climate change1%

C07KPeptides0%

PatentTitleYear

10,772,8932-(morpholin-4-yl)-1,7-naphthyridines2020 10,729,6805-substituted 2-(morpholin-4-yl)-1,7-naphthyridines2020 10,717,749Macrocyclic sulfondiimine compounds2020 10,604,532Substituted benzylindazoles for use as BUB1 kinase inhibitors in the treatment of hyperproliferative diseases2020 10,428,0443-amino-1,5,6,7-tetrahydro-4H-indol-4-ones2019 10,428,0634H-pyrrolo[3,2-C]pyridin-4-one derivatives2019 10,350,206Benzyl substituted indazoles as BUB1 inhibitors2019 10,308,6291H-pyrrol-3-amines2019 10,266,548Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases2019 10,227,2993-amino-1,5,6,7-tetrahydro-4H-indol-4-ones2019 10,214,542Modified macrocyclic compounds2019 9,993,4842-(morpholin-4-yl)-1,7-naphthyridines2018 9,962,3894-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group2018 9,963,464Macrocyclic compounds2018 9,902,716'Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfone group'2018 9,884,849'Fluorinated benzofuranyl-pyrimidine derivatives containing a sulfoximine group'2018 9,877,954'5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group'2018 9,856,242'5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group'2018 9,790,189'Disubstituted 5-fluoro pyrimidine derivatives containing a sulfondiimine group'2017 9,770,445'Sulfoximine substituted 5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives and their use as CDK9 kinase inhibitors'2017 9,765,058'Substituted benzylpyrazoles'2017 9,745,285'Heteroaryl substituted pyrazoles'2017 9,708,293'N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfone group'2017 9,682,995'Amino-substituted isothiazoles'2017 9,682,974'Heteroaryl substituted pyrazoles'2017 9,676,766'Triazolopyridines'2017 9,670,161'5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfone group'2017 9,670,202'Substituted triazolopyridines'2017 9,669,034'4-aryl-N-phenyl-1,3,5-triazin-2-amines containing a sulfoximine group'2017 9,663,510'Substituted triazolopyridines and their use as TTK inhibitors'2017 9,650,340'5-fluoro-N-(pyridin-2-yl)pyridin-2-amine derivatives containing a sulfoximine group'2017 9,650,361'N-(pyridin-2-yl)pyrimidin-4-amine derivatives containing a sulfoximine group'2017 9,643,953'Substituted benzylpyrazoles'2017 9,586,958'Prodrug derivatives of substituted triazolopyridines'2017 9,555,022'Substituted triazolopyridines'2017 9,549,932'2-(morpholin-4-yl)-1,7-naphthyridines'2017 9,512,130'Substituted imidazopyridazines'2016 9,512,126'Substituted imidazopyridazines'2016 9,499,492'4-(ortho)-fluorophenyl-5-fluoropyrimidin-2-yl amines containing a sulfoximine group'2016 9,468,642'Imidazopyrazines'2016 9,422,268'Substituted benzylpyrazoles'2016 9,416,125'Substituted cycloalkenopyrazoles as BUB1 inhibitors for the treatment of cancer'2016 9,388,140'Substituted benzimidazoles'2016 9,340,528'Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors'2016 9,284,317'Substituted imidazo[1,2-a]pyrazines as MPS-1 inhibitors'2016 9,265,763'Substituted benzylindazoles for use as Bub1 kinase inhibitors in the treatment of hyperproliferative diseases'2016 9,260,412'Substituted benzylpyrazoles'2016 9,255,100'Substituted imidazopyridazines'2016 9,212,184'6-thio-substituted imidazo[1,2-a]pyrazines as Mps-1 inhibitors'2015 9,199,999'Substituted imidazopyrazines'2015 9,133,171'Disubstituted 5-fluoro pyrimidine derivatives containing a sulfoximine group'2015 9,108,926'Disubstituted 5-fluoro-pyrimidines'2015 8,993,630'Substituted sulphonamido phenoxybenzamides'2015 8,916,557'Substituted 4-Aryl-N-phenyl-1,3,5-triazin-2-amines'2014 8,802,686'Sulfone-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as a medicine'2014 8,735,412'Sulfoximine-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as medicine'2014 8,729,082'Substituted imidazoquinoxalines'2014 8,551,980'Substituted triazolopyridines'2013 8,524,722'Substituted tricyclic compounds and methods of use thereof'2013 8,507,510'Sulfoximine-substituted pyrimidines as CDK- and/or VEGF inhibitors, their production and use as pharmaceutical agents'2013 7,943,629'Sulphimides as protein kinase inhibitors'2011 7,598,260'CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents'2009 7,511,059'Thiazolidinones, their production and use as pharmaceutical agents'2009 7,456,191'N-Aryl-sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents'2008 7,378,406'Use of antiprogestins for prophylaxis and treatment of hormone-dependent diseases'2008 7,338,958'Sulfoximine-substituted pyrimidines as CDK-and/or VEGF inhibitors, their production and use as pharmaceutical agents'2008 7,335,775'Effector conjugates, process for their production and their pharmaceutical use'2008 7,312,225'Macrocyclic pyrimidines, their production and use as pharmaceutical agents'2007 7,291,624'CDK-inhibitory pyrimidines, their production and use as pharmaceutical agents'2007 7,288,547'CDK-inhibitory 2-heteroaryl-pyrimidines, their production and use as pharmaceutical agents'2007 7,235,561'Compound and a composition including such a compound'2007 7,129,254'Effector conjugates, process for their production and their pharmaceutical use'2006 6,747,046'Substituted N-(1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl) derivatives, their production and use as pharmaceutical agents'2004

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2004–2020Based in Berlin, DE· patent location history

2013–2020Patents assigned to BAYER IP GMBH (25)· patent assignee history

2013–2017Patents assigned to SIEMEISTER GERHARD (20)· patent assignee history

2013–2017Patents assigned to LIENAU PHILIP (16)· patent assignee history

2013–2017Patents assigned to KOSEMUND DIRK (13)· patent assignee history

2016–2020Patents assigned to Bayer Pharma AG (35)· patent assignee history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
Bayer Pharma AG	35	2016–2020
BAYER IP GMBH	25	2013–2020
SIEMEISTER GERHARDself	20	2013–2017
LIENAU PHILIP	16	2013–2017
KOSEMUND DIRK	13	2013–2017

Locations

Location	Patents	Span
Berlin, DE	73	2004–2020